AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. **(currently amended):** A method for inhibiting CCR3, comprising administering to a subject an effective amount of a compound having CCR3 antagonistic activity, wherein said compound is ~~A pharmaceutical composition which contains, as an active ingredient, a compound~~ represented by the following formula (I), a pharmaceutically acceptable acid addition salt thereof, or a pharmaceutically acceptable C_1 to C_6 alkyl addition salt thereof, ~~and which has CCR3 antagonistic activity,~~



(I)

~~[~~wherein, R^1 represents a phenyl group, a C_3 to C_8 cycloalkyl group, or an aromatic heterocyclic group having one to three atoms of oxygen, sulfur and/or nitrogen as heteroatoms, provided that the phenyl group or the aromatic heterocyclic group in the above-mentioned R^1 may be condensed with a benzene ring, or an aromatic heterocyclic group having one to three atoms of oxygen, sulfur and/or nitrogen as heteroatoms to form a condensed ring, further provided that the phenyl group, the C_3 to C_8 cycloalkyl group, the aromatic heterocyclic group or the condensed ring may be substituted by one or more ~~the arbitrary number of~~ halogen atoms, hydroxy groups, cyano groups, nitro groups, carboxyl groups, carbamoyl groups, C_1 to C_6 alkyl

groups, C_3 to C_8 cycloalkyl groups, C_2 to C_6 alkenyl groups, C1 to C6 alkoxy groups, C_1 to C_6 alkylthio groups, C_3 to C_5 alkylene groups, C_2 to C_4 alkylenoxy groups, C_1 to C_3 alkylenedioxy groups, phenyl groups, phenoxy groups, phenylthio groups, benzyl groups, benzyloxy groups, benzoylamino groups, C_2 to C_7 alkanoyl groups, C_2 to C_7 alkoxycarbonyl groups, C_2 to C_7 alkanoyloxy groups, C_2 to C_7 alkanoylamino groups, C_2 to C_7 N-alkylcarbamoyl groups, C_4 to C_9 N-cycloalkylcarbamoyl groups, C_1 to C_6 alkylsulfonyl groups, C_3 to C_8 (alkoxycarbonyl)methyl groups, N-phenylcarbamoyl groups, piperidinocarbonyl groups, morpholinocarbonyl groups, 1-pyrrolidinylcarbonyl groups, divalent groups represented by the formula: -NH(C=O)O-, divalent groups represented by the formula: -NH(C=S)O-, amino groups, mono(C_1 to C_6 alkyl)amino groups or di(C_1 to C_6 alkyl)amino groups, and further provided that the substituents of the phenyl group, the C_3 to C_8 cycloalkyl group, the aromatic heterocyclic group or the condensed ring may further be substituted by one or more ~~the arbitrary number of~~ halogen atoms, hydroxy groups, amino groups, trifluoromethyl groups, C_1 to C_6 alkyl groups or C_1 to C_6 alkoxy groups; ~~groups.~~

R^2 represents a hydrogen atom, a C_1 to C_6 alkyl group, a C_2 to C_7 alkoxycarbonyl group, a hydroxy group or a phenyl group, provided that the C_1 to C_6 alkyl group or the phenyl group in R^2 may be substituted by one or more ~~the arbitrary number of~~ halogen atoms, hydroxy groups, C_1 to C_6 alkyl groups or C_1 to C_6 alkoxy groups, and provided that when j is 0, R^2 is not a hydroxy group; ~~group.~~

j represents an integer of 0 to 2; ~~2.~~

k represents an integer of 0 to 2; ~~2.~~

m represents an integer of 2 to 4; ~~4.~~

n represents 0 or 1; ~~1.~~

R^3 represents a hydrogen atom or a C_1 to C_6 alkyl group which may be substituted by one or two phenyl groups which may be substituted by the same or different ~~arbitrary~~ numbers of halogen atoms, hydroxy groups, C_1 to C_6 alkyl groups or C_1 to C_6 alkoxy groups; ~~groups, respectively).~~

R^4 and R^5, which may be the same or different~~ly~~, represent a hydrogen atom, a hydroxy group, a phenyl group or a C_1 to C_6 alkyl group, ~~respectively,~~ and the C_1 to C_6 alkyl group represented by R^4 and/or R^5 may be substituted by one or more ~~the arbitrary number of~~ halogen atoms, hydroxy groups, cyano groups, nitro groups, carboxyl groups, carbamoyl groups, mercapto groups, guanidino groups, C_3 to C_8 cycloalkyl groups, C_1 to C_6 alkoxy groups, C_1 to C_6 alkylthio groups, phenyl groups ~~(~~which may be substituted by one or more ~~the arbitrary number of~~ halogen atoms, hydroxy groups, C_1 to C_6 alkyl groups, C_1 to C_6 alkoxy groups or benzyloxy groups, phenoxy groups, benzyloxy groups, benzyloxycarbonyl groups, C_2 to C_7 alkanoyl groups, C_2 to C_7 alkoxycarbonyl groups, C_2 to C_7 alkanoyloxy groups, C_2 to C_7 alkanoylamino groups, C_2 to C_7 N-alkylcarbamoyl groups, C_1 to C_6 alkylsulfonyl groups, amino groups, mono(C_1 to C_6 alkyl)amino groups, di(C_1 to C_6 alkyl)amino groups or aromatic heterocyclic groups ~~(~~having one to three atoms of oxygen, sulfur and/or nitrogen as heteroatoms~~)~~, or condensed rings formed by the condensation of the aromatic heterocyclic group with a benzene ring, or R^4 and R^5 may together form a three to six-membered cyclic hydrocarbon; ~~hydrocarbon.~~

p represents 0 or 1; ~~1.~~

q represents 0 or 1; ~~1.~~

G represents a group represented by -CO-, -SO_2-, -CO-O-, -NR^7-CO-, -CO-NR^7-, -NH-CO-NH-, -NH-CS-NH-, -NR^7-SO_2-, -SO_2-NR^7-, -NH-CO-O-, or -O-CO-NH-, provided that R^7 is a hydrogen atom or a C_1 to C_6 alkyl group, or R^7 may form a C_2 to C_5 alkylene group together with $\underline{R^5}$; ~~R^5~~.

R^6 represents a phenyl group, a C_3 to C_8 cycloalkyl group, a C_3 to C_6 cycloalkenyl group, a benzyl group or an aromatic heterocyclic group having one to three atoms of oxygen, sulfur and/or nitrogen as heteroatoms, provided that the phenyl group, the benzyl group or the aromatic heterocyclic group represented by ~~in the above mentioned~~ R^6 may be condensed, to make a condensed ring, with a benzene ring or an aromatic heterocyclic group having one or three atoms of oxygen, sulfur and/or nitrogen as heteroatoms, further provided that the phenyl group, the C_3 to C_8 cycloalkyl group, the C_3 to C_6 cycloalkenyl group, the benzyl group, the aromatic heterocyclic group or the condensed ring represented by ~~in the above mentioned~~ R^6 may be substituted by one or more ~~the arbitrary number of~~ halogen atoms, hydroxy groups, mercapto groups, cyano groups, nitro groups, thiocyanato groups, carboxyl groups, carbamoyl groups, trifluoromethyl groups, C_1 to C_6 alkyl groups, C_3 to C_6 cycloalkyl groups, C_2 to C_6 alkenyl groups, C_1 to C_6 alkoxy groups, C_3 to C_8 cycloalkyloxy groups, C_1 to C_6 alkylthio groups, C_1 to C_3 alkylenedioxy groups, phenyl groups, phenoxy groups, phenylamino groups, benzyl groups, benzoyl groups, phenylsulfinyl groups, phenylsulfonyl groups, 3-phenylureido groups, C_2 to C_7 alkanoyl groups, C_2 to C_7 alkoxycarbonyl groups, C_2 to C_7 alkanoyloxy groups, C_2 to C_7 alkanoylamino group, C_2 to C_7 N-alkylcarbamoyl groups, C_1 to C_6 alkylsulfonyl groups, phenylcarbamoyl groups, N,N-di(C_1 to C_6 alkyl)sulfamoyl groups, amino groups, mono(C_1 to C_6

alkyl)amino groups, di(C_1 to C_6 alkyl)amino groups, benzylamino groups, C_2 to C_7 (alkoxycarbonyl)amino groups, C_1 to C_6 (alkylsulfonyl)amino groups or bis(C_1 to C_6 alkylsulfonyl)amino groups, and further provided that the substituents of the phenyl group, the C_3 to C_8 cycloalkyl group, the C_3 to C_8 cycloalkenyl group, the benzyl group, the aromatic heterocyclic group, or the condensed ring may further be substituted by one or more ~~the arbitrary number of~~ halogen atoms, cyano groups, hydroxy groups, amino groups, trifluoromethyl groups, C_1 to C_6 alkyl groups, C_1 to C_6 alkoxy groups, C_1 to C_6 alkylthio groups, mono(C_1 to C_6 alkyl)amino groups, or di(C_1 to C_6 alkyl)amino groups; and

wherein when k is 1 and m is 2, then n is not 1.

2. **(currently amended):** The method ~~pharmaceutical composition having the CCR3 antagonistic action~~ according to Claim 1, wherein k is 1 and m is 2 in the above-mentioned formula (I).

3. **(withdrawn):** The method ~~pharmaceutical composition having the CCR3 antagonistic action~~ according to Claim 1, wherein k is 0 and m is 3 in the above-mentioned formula (I).

4. **(withdrawn):** The method ~~pharmaceutical composition having the CCR3 antagonistic action~~ according to Claim 1, wherein k is 1 and m is 3 in the above-mentioned formula (I).

5. **(withdrawn):** The method ~~pharmaceutical composition having the CCR3 antagonistic action~~ according to Claim 1, wherein k is 2 and m is 2 in the above-mentioned formula (I).

6. **(withdrawn):** The method according to Claim 1, wherein k is 1 and m is 4 in the above-mentioned formula (I).

7. **(currently amended):** A method for treatment and/or prevention of allergic disease, asthma, allergic rhinitis, atopic dermatitis, urticaria, contact dermatitis, allergic conjunctivitis, inflammatory bowel disease, ulcerative colitis, Crohn disease, eosinophilia, eosinophilic gastroentereitis, eosinophilic enteropathy, eosinophilic fasciitis, eosinophilic granuloma, eosinophilic pustular folliculitis, eosinophilic pneumonia, eosinophilic leukemia, and Acquired Immuno-Deficiency Syndrome (AIDS), comprising administering to a subject ~~pharmaceutical composition which contains, as an active ingredient,~~ an effective amount of a compound having CCR3 antagonistic activity, wherein said ~~the~~ compound is represented by the above-mentioned formula (I), the pharmaceutically acceptable acid addition salt thereof, or the pharmaceutically acceptable C1 to C6 alkyl addition salt thereof, ~~and which is used for treating or preventing a disease concerned with CCR3.~~

wherein, R^1 represents a phenyl group, a C_3 to C_8 cycloalkyl group, or an aromatic heterocyclic group having one to three atoms of oxygen, sulfur and/or nitrogen as heteroatoms, provided that the phenyl group or the aromatic heterocyclic group in the above-mentioned R^1 may be condensed with a benzene ring, or an aromatic heterocyclic group having one to three

atoms of oxygen, sulfur and/or nitrogen as heteroatoms to form a condensed ring, further provided that the phenyl group, the C_3 to C_8 cycloalkyl group, the aromatic heterocyclic group or the condensed ring may be substituted by one or more halogen atoms, hydroxy groups, cyano groups, nitro groups, carboxyl groups, carbamoyl groups, C_1 to C_6 alkyl groups, C_3 to C_8 cycloalkyl groups, C_2 to C_6 alkenyl groups, C1 to C6 alkoxy groups, C_1 to C_6 alkylthio groups, C_3 to C_5 alkylene groups, C_2 to C_4 alkylenoxy groups, C_1 to C_3 alkylenedioxy groups, phenyl groups, phenoxy groups, phenylthio groups, benzyl groups, benzyloxy groups, benzoylamino groups, C_2 to C_7 alkanoyl groups, C_2 to C_7 alkoxycarbonyl groups, C_2 to C_7 alkanoyloxy groups, C_2 to C_7 alkanoylamino groups, C_2 to C_7 N-alkylcarbamoyl groups, C_4 to C_9 N-cycloalkylcarbamoyl groups, C_1 to C_6 alkylsulfonyl groups, C_3 to C_8 (alkoxycarbonyl)methyl groups, N-phenylcarbamoyl groups, piperidinocarbonyl groups, morpholinocarbonyl groups, 1-pyrrolidinylcarbonyl groups, divalent groups represented by the formula: -NH(C=O)O-, divalent groups represented by the formula: -NH(C=S)O-, amino groups, mono(C_1 to C_6 alkyl)amino groups or di(C_1 to C_6 alkyl)amino groups, and further provided that the substituents of the phenyl group, the C_3 to C_8 cycloalkyl group, the aromatic heterocyclic group or the condensed ring may further be substituted by one or more the arbitrary number of halogen atoms, hydroxy groups, amino groups, trifluoromethyl groups, C_1 to C_6 alkyl groups or C_1 to C_6 alkoxy groups; groups.

R^2 represents a hydrogen atom, a C_1 to C_6 alkyl group, a C_2 to C_7 alkoxycarbonyl group, a hydroxy group or a phenyl group, provided that the C_1 to C_6 alkyl group or the phenyl group in R^2 may be substituted by one or more halogen atoms, hydroxy groups, C_1 to C_6 alkyl groups or C_1 to C_6 alkoxy groups, and provided that when j is 0, R^2 is not a hydroxy group;

j represents an integer of 0 to 2;

k represents an integer of 0 to 2;

m represents an integer of 2 to 4;

n represents 0 or 1;

R^3 represents a hydrogen atom or a C_1 to C_6 alkyl group which may be substituted by one or two phenyl groups which may be substituted by the same or different numbers of halogen atoms, hydroxy groups, C_1 to C_6 alkyl groups or C_1 to C_6 alkoxy groups;

R^4 and R^5, which may be the same or different, represent a hydrogen atom, a hydroxy group, a phenyl group or a C_1 to C_6 alkyl group, and the C_1 to C_6 alkyl group represented by R^4 and/or R^5 may be substituted by one or more halogen atoms, hydroxy groups, cyano groups, nitro groups, carboxyl groups, carbamoyl groups, mercapto groups, guanidino groups, C_3 to C_8 cycloalkyl groups, C_1 to C_6 alkoxy groups, C_1 to C_6 alkylthio groups, phenyl groups which may be substituted by one or more halogen atoms, hydroxy groups, C_1 to C_6 alkyl groups, C_1 to C_6 alkoxy groups or benzyloxy groups, phenoxy groups, benzyloxy groups, benzyloxycarbonyl groups, C_2 to C_7 alkanoyl groups, C_2 to C_7 alkoxycarbonyl groups, C_2 to C_7 alkanoyloxy groups, C_2 to C_7 alkanoylamino groups, C_2 to C_7 N-alkylcarbamoyl groups, C_1 to C_6 alkylsulfonyl groups, amino groups, mono(C_1 to C_6 alkyl)amino groups, di(C_1 to C_6 alkyl)amino groups or aromatic heterocyclic groups (having one to three atoms of oxygen, sulfur and/or nitrogen as heteroatoms), or condensed rings formed by the condensation of the aromatic heterocyclic group with a benzene ring, or R^4 and R^5 may together form a three to six-membered cyclic hydrocarbon;

p represents 0 or 1;

q represents 0 or 1;

G represents a group represented by -CO-, -SO_2-, -CO-O-, -NR^7-CO-, -CO-NR^7-, -NH-CO-NH-, -NH-CS-NH-, -NR^7-SO_2-, -SO_2-NR^7-, -NH-CO-O-, or -O-CO-NH-, provided that R^7 is a hydrogen atom or a C_1 to C_6 alkyl group, or R^7 may form a C_2 to C_5 alkylene group together with R^5;

R^6 represents a phenyl group, a C_3 to C_8 cycloalkyl group, a C_3 to C_6 cycloalkenyl group, a benzyl group or an aromatic heterocyclic group having one to three atoms of oxygen, sulfur and/or nitrogen as heteroatoms, provided that the phenyl group, the benzyl group or the aromatic heterocyclic group represented by R^6 may be condensed, to make a condensed ring, with a benzene ring or an aromatic heterocyclic group having one or three atoms of oxygen, sulfur and/or nitrogen as heteroatoms, further provided that the phenyl group, the C_3 to C_8 cycloalkyl group, the C_3 to C_6 cycloalkenyl group, the benzyl group, the aromatic heterocyclic group or the condensed ring represented by R^6 may be substituted by one or more halogen atoms, hydroxy groups, mercapto groups, cyano groups, nitro groups, thiocyanato groups, carboxyl groups, carbamoyl groups, trifluoromethyl groups, C_1 to C_6 alkyl groups, C_3 to C_6 cycloalkyl groups, C_2 to C_6 alkenyl groups, C_1 to C_6 alkoxy groups, C_3 to C_8 cycloalkyloxy groups, C_1 to C_6 alkylthio groups, C_1 to C_3 alkylenedioxy groups, phenyl groups, phenoxy groups, phenylamino groups, benzyl groups, benzoyl groups, phenylsulfinyl groups, phenylsulfonyl groups, 3-phenylureido groups, C_2 to C_7 alkanoyl groups, C_2 to C_7 alkoxycarbonyl groups, C_2 to C_7 alkanoyloxy groups, C_2 to C_7 alkanoylamino group, C_2 to C_7 N-alkylcarbamoyl groups, C_1 to C_6 alkylsulfonyl groups,

phenylcarbamoyl groups, N,N-di(C_1 to C_6 alkyl)sulfamoyl groups, amino groups, mono(C_1 to C_6 alkyl)amino groups, di(C_1 to C_6 alkyl)amino groups, benzylamino groups, C_2 to C_7 (alkoxycarbonyl)amino groups, C_1 to C_6 (alkylsulfonyl)amino groups or bis(C_1 to C_6 alkylsulfonyl)amino groups, and further provided that the substituents of the phenyl group, the C_3 to C_8 cycloalkyl group, the C_3 to C_8 cycloalkenyl group, the benzyl group, the aromatic heterocyclic group, or the condensed ring may further be substituted by one or more halogen atoms, cyano groups, hydroxy groups, amino groups, trifluoromethyl groups, C_1 to C_6 alkyl groups, C_1 to C_6 alkoxy groups, C_1 to C_6 alkylthio groups, mono(C_1 to C_6 alkyl)amino groups, or di(C_1 to C_6 alkyl)amino groups; and

wherein when k is 1 and m is 2, then n is not 1.

8. **(currently amended):** The method according to Claim 7, wherein the disease treatable and/or preventable by administration of a CCR3 antagonist ~~The pharmaceutical composition for treating or preventing the disease according to Claim 7, wherein the disease~~ is an allergic disease.

9. **(currently amended):** The method according to Claim 7, wherein the disease treatable and/or preventable by administration of a CCR3 antagonist ~~The pharmaceutical composition for treating or preventing the disease according to Claim 7, wherein the disease~~ is asthma, allergic rhinitis, atopic dermatitis, urticaria, contact dermatitis, or allergic conjunctivitis.

10. **(currently amended):** The method according to Claim 7, wherein the disease treatable and/or preventable by administration of a CCR3 antagonist ~~The pharmaceutical composition for treating or preventing the disease according to Claim 7, wherein the disease~~ is an inflammatory bowel disease.

11. **(currently amended):** The method according to Claim 7, wherein the disease treatable and/or preventable by administration of a CCR3 antagonist ~~The pharmaceutical composition for treating or preventing the disease according to Claim 7, wherein the disease~~ is AIDS.